person · Reporting owner
Giordano Christopher Thomas
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director · CEO | September 11, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TENAX THERAPEUTICS, INC.
Report date September 11, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,174 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Purchase · Acquired 6,000 · Balance 17,324 F1: This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Row 2 · 2026-09-15 · Purchase · Acquired 4,850 · Balance 22,174 F2: This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 450,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 450,000 F3: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.89 · Expires 2035-05-16 | Direct | 1,400,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,400,000 F4: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2034-05-17 | Direct | 218 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 218 F5: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 1,241,500 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,241,500 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 125 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 125 F6: The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,152.00 · Expires 2031-07-06 | Direct | 157 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 157 F7: The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
F4: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
F5: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
F6: The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F7: The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 01:38 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 4,850 | $1.82 | $8,837.19 |
DisclosureSEC source: 0001871714-26-000002 · primary_doc.xml · nonDerivative · entry 2 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,174 F2 · price: This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 11, 2026 Filed Sep 16, 2026 01:38 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 6,000 | $1.88 | $11,250.00 |
DisclosureSEC source: 0001871714-26-000002 · primary_doc.xml · nonDerivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,324 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 13, 2026 Filed Jul 14, 2026 23:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001193125-26-303600 · ownership.xml · derivative · entry 4 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,241,500 Underlying: Common Stock · 8,500 shares Expires 2034-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2026 Filed Jul 14, 2026 23:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionStock Option (right to buy) · Derivative | 219 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001193125-26-303600 · ownership.xml · derivative · entry 3 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218 Underlying: Common Stock · 219 shares Expires 2034-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. Read SEC document |
| July 13, 2026 Filed Jul 14, 2026 23:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionCommon Stock | 8,500 | $5.94 | $50,490.00 |
DisclosureSEC source: 0001193125-26-303600 · ownership.xml · nonDerivative · entry 2 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The aggregate exercise price was paid in cash. Read SEC document |
| July 13, 2026 Filed Jul 14, 2026 23:29 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionCommon Stock | 219 | $3.55 | $777.23 |
DisclosureSEC source: 0001193125-26-303600 · ownership.xml · nonDerivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The aggregate exercise price was paid in cash. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:37 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001871714-26-000001 · primary_doc.xml · derivative · entry 2 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. Read SEC document |
| November 20, 2025 Filed Nov 20, 2025 23:38 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 538 | $7.59 | $4,082.72 |
DisclosureSEC source: 0001871714-25-000002 · primary_doc.xml · nonDerivative · entry 3 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,605 F3 · price: This transaction was executed in multiple trades at prices ranging from $7.54 to $7.73. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 23:38 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 455 | $7.51 | $3,416.64 |
DisclosureSEC source: 0001871714-25-000002 · primary_doc.xml · nonDerivative · entry 2 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,067 F2 · price: This transaction was executed in multiple trades at prices ranging from $7.35 to $7.62. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 23:38 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 1,612 | $7.75 | $12,500.42 |
DisclosureSEC source: 0001871714-25-000002 · primary_doc.xml · nonDerivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,612 F1 · price: This transaction was executed in multiple trades at prices ranging from $7.47 to $7.68. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:50 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 1,400,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001654954-25-005949 · section16.xml · derivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2035-05-16 F1 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 01:02 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001654954-24-015474 · section16.xml · derivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2034-12-10 Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:00 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 437 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001654954-24-006744 · section16.xml · derivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437 Underlying: Common Stock · 437 shares Expires 2034-05-17 F1 · derivative.exercise_date: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. Read SEC document |
| June 09, 2022 Filed Jun 11, 2022 01:15 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001654954-22-008236 · section16.xml · derivative · entry 1 Giordano Christopher Thomas · CIK 0001871714 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The options vest and become exercisable as follows: options with respect to 50,000 underlying shares of Common Stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.